오파투무맙
|
|
오파투무맙 속성
- 물리적 상태
- Liquid
- 색상
- Colorless to light yellow
안전
유해 물질 데이터 | 679818-59-8(Hazardous Substances Data) |
---|
오파투무맙 C화학적 특성, 용도, 생산
개요
Considered as the most common form of leukemia in adults, CLL is characterized by the accumulation of abnormal B lymphocytes and manifests itself as lymph node enlargement and bone marrow failure in symptomatic patients. Ofatumumab is the second marketed mAb to target CD20. Compared to its predecessor,it is a fully human mAb that was generated via transgenic mouse and hybridoma technology. In addition to the Fab portion that recognizes CD20, the Fc domain mediates immune effector functions to lyse cells via complement-dependent cytotoxicity (CDC) and antibody-dependent, cell-mediated cytotoxicity (ADCC). Ofatumumab targets a different, discontinuous epitope on CD20 than rituximab; it binds specifically to both the small and large extracellular loops of the CD20 molecule expressed on normal B lymphocytes and on B-cell CL, and its binding does not induce receptor internalization nor shedding from the cell surface. In addition to targeting a different epitope on CD20, ofatumumab also exhibits a slower off-rate. These characteristics have been proposed as reasons for its ability to lyse rituximab-resistant cells that express low levels of CD20 and for its greater in vitro activity against CLL cells versus rituximab.The most common adverse events were neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.
Originator
Genmab (Denmark)상표명
Arzerra오파투무맙 준비 용품 및 원자재
원자재
준비 용품
오파투무맙 공급 업체
글로벌( 27)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
TargetMol Chemicals Inc. | +1-781-999-5354 |
support@targetmol.com | United States | 19973 | 58 |
Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 |
masar@topule.com | China | 8474 | 58 |
Aladdin Scientific | +1-+1(833)-552-7181 |
sales@aladdinsci.com | United States | 57511 | 58 |
LGM Pharma | 1-(800)-881-8210 |
inquiries@lgmpharma.com | United States | 2127 | 70 |
Dalian Meilun Biotech Co., Ltd. | 0411-62910999 13889544652 |
meilunui@163.com | China | 4672 | 58 |
NCE Biomedical Co.,Ltd. | 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
China | 1494 | 55 | |
Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 |
info@efebio.com | China | 9707 | 58 |
ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 |
2853530910@QQ.com | China | 8014 | 62 |
Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 |
981810490@qq.com | China | 1565 | 58 |
Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 |
422450190@qq.com | China | 10351 | 58 |
오파투무맙 관련 검색:
Follicle stimulating hormone
Secukinumab
Daratumumab
OMALIZUMAB
Dulaglutide
Trastuzumab emtansine
Ranibizumab
palivizumab
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
Eculizumab
Panitumumab
Bortezomib
Ibrutinib
mepolizumab
Matuzumab
ticilimumab tremelimumab
CNTO 148
belimumab